Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Atorvastatin · Atorvaliq, Lipitor

Small molecule · Inhibitor of HMG-CoA reductase (HMGCR) · developed by Upjohn

Being checked. Our sources disagree on some details of this drug, so parts of this page may be wrong until a person has reviewed it.
Approved FDA, Dec 1996
9 Registered trials

What is Atorvastatin?

Atorvastatin is a statin that competitively inhibits HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis in the liver. It also increases hepatic LDL receptor numbers, enhancing LDL uptake and clearance. It is studied in atherosclerotic cardiovascular disease, hypercholesterolemia, dyslipidemias, rheumatoid arthritis, and nonalcoholic steatohepatitis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Atorvaliq, Lipitor
Drug type
Small molecule
Targets
HMG-CoA reductase (HMGCR), LDL receptor (LDLR) (secondary target)
Mechanism
Inhibitor of HMG-CoA reductase (HMGCR)
Pathways
cholesterol synthesis, mevalonate pathway, LDL uptake and catabolism
Therapy area
Cardiovascular, Metabolic
Developer
Upjohn
In trials of
AKBA, ALGS, ALT, AZN, CPIX, EOCN, LKFT, MDGL, NVS
FDA status
Approved as Atorvaliq, Lipitor (December 17, 1996), NDA020702 · FDA label

✅ FDA-approved uses

From the indications section of the FDA label (version of Apr 15, 2024). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03611010 Phase 2 Hypercholesterolemia Completed CPIX
NCT07534592 Phase 1 Healthy Participants Active not recruiting AZN
NCT06191991 Phase 1 Healthy Volunteers Completed ALGS
NCT04972396 Phase 1 NASH - Nonalcoholic Steatohepatitis Completed ALT
NCT04608344 Phase 1 Rheumatoid Arthritis Completed LKFT
NCT03760848 Phase 1 Healthy Completed EOCN
NCT03801733 Phase 1 Drug Interaction Potentiation Completed AKBA
NCT02749578 Phase 1 Healthy Completed MDGL
NCT06858332 N/A Atherosclerotic Cardiovascular Disease Recruiting NVS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Atherosclerotic Cardiovascular DiseaseHealthy ParticipantsDrug Interaction PotentiationDyslipidemiasHealthyHealthy VolunteersHypercholesterolemiaNASH - Nonalcoholic SteatohepatitisRheumatoid Arthritis

Other drugs acting on HMGCR

Sources

Updated Nov 15, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.